Let’s Get Started
There are several options that may help you afford your Genentech medicine. Answer a few simple questions to find out which one might be right for you.
Do you have health insurance?
Do you have commercial health insurance?What does this mean?
Are you already getting financial assistance to help pay for your medicine?What does this mean?
Are you taking Pulmozyme for an FDA-approved use?
Are you 18 years of age or older, or have a legal guardian over the age of 18?
Is the co-pay for Pulmozyme over $30 per month?
You Might Qualify for a Referral to the Pulmozyme Co-pay Card Program
Pulmozyme Access Solutions can refer you to the Pulmozyme Co-pay Card Program. It can help you with the out-of-pocket costs of your Genentech medicine, if you’re eligible.*
*In order to be eligible for the Pulmozyme Co-pay Card Program, the patient must confirm that they meet the eligibility criteria and agree to the rules set forth in the terms and conditions for the program. Please visit PulmozymeCopayCard.com for the full list of terms and conditions.
You Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
If you need help with your co-pay for your Genentech medicine, we can refer you to an independent co-pay assistance foundation.*
*In order to be eligible for the Pulmozyme Co-pay Card Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit PulmozymeCopayCard.com for the full list of terms and conditions.
You Might Qualify for a Referral to the Genentech® Access to Care Foundation, or GATCF
GATCF can help you receive your Genentech medicine free of charge, if you qualify.*
*If you have health insurance, you must have already tried other types of patient assistance to qualify for free Genentech medicine from GATCF. This includes the Pulmozyme Co-pay Card Program and support from independent co-pay assistance foundations. You must also meet financial criteria. If you do not have insurance, you must meet different financial criteria.
Important Safety Information & Indication
What it Treats
Pulmozyme® (dornase alfa) is indicated for daily administration along with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.
In CF patients with an FVC ≥40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring injectable antibiotics.
Important Safety Information
Pulmozyme should not be used in patients who are allergic to any of its ingredients.
Patients may experience the following when using Pulmozyme: change in or loss of their voice, discomfort in the throat, rash, chest pain, red watery eyes, runny nose, lowering of lung function, fever, indigestion and shortness of breath. There have been no reports of severe allergic reactions caused by the administration of Pulmozyme. Mild to moderate hives and mild skin rash have been observed and have been short-lived.
You are encouraged to report side effects to Genentech and the FDA. You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.
For further information, please see the Pulmozyme full Prescribing Information.
The safety and effectiveness of Pulmozyme have been established in patients 5 years of age and older. While clinical trial data are limited in patients younger than 5 years of age, the use of PULMOZYME should be considered for pediatric CF patients who may experience potential benefit in lung function or who may be at risk of respiratory tract infection.
The safety of Pulmozyme given by daily inhalation for 2 weeks has been studied using 98 CF patients with 65 of them aged 3 months to ™ reusable nebulizer (which uses a face mask instead of a mouthpiece) was used in patients who were unable to show that they could breathe in or out using their mouth throughout the entire treatment period. Overall, the kind of side effects observed in children was similar to those seen in larger trials in older patients.